Start with the study design, population, outcomes, limitations, and open questions—not a verdict. Every factual sentence is pinned to an explicitly reviewed source snapshot.
3 reviewed sources3 study sectionsv1 current review
Reviewed through
August 18, 2026
Last integrity check
August 19, 2026
Latest notice date
None registered
This source set contains a two-person uncontrolled safety pilot, a narrative review dominated by preclinical research, and a recruiting Phase 2 protocol with no posted results. It does not establish human efficacy.↗↗↗
Conditions
Safety observations · Acute hamstring strain
Population
Healthy adults · Adults with acute injury
Design
Uncontrolled study · Trial protocol · Narrative review
The reviewed Phase 2 trial reported greater mean weight reduction with cagrilintide than placebo across the tested groups. A single 26-week dose-finding trial does not establish long-term outcomes or uncommon harms.↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
None registered
The short monotherapy trial reported improved glycated hemoglobin and weight measures. The larger outcomes trial established cardiovascular noninferiority but did not meet its superiority criterion for major cardiovascular events.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
None registered
In the reviewed pelvic-pain trial, both treatment groups improved without a significant between-group difference. In the prostate-cancer trial, the oral comparator produced more sustained testosterone suppression than leuprolide; that biochemical endpoint does not establish a difference in cancer survival.↗↗
Conditions
Endometriosis-associated pelvic pain · Advanced prostate cancer
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
None registered
The reviewed weight-management trial reported greater mean weight reduction than placebo, and the reviewed cardiovascular trial reported fewer primary cardiovascular events in a high-risk type 2 diabetes population. The findings remain specific to the studied populations and trial conditions.↗↗
Conditions
Obesity · Overweight · Type 2 diabetes · Cardiovascular outcomes
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
March 1, 2022
The short trial reported reduced growth-hormone and insulin-like growth factor I levels with octreotide. In the selected-responder Phase 3 trial, oral octreotide met the prespecified noninferiority criterion against injectable therapy for maintaining biochemical response.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 18, 2026
Last integrity check
August 19, 2026
Latest notice date
None registered
Both reviewed Phase 2 trials reported reductions in body weight, and the type 2 diabetes trial also reported lower glycated hemoglobin. These mid-stage studies do not resolve long-term outcomes or broader population effects.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 18, 2026
Last integrity check
August 19, 2026
Latest notice date
None registered
In the reviewed trials, semaglutide was associated with greater weight reduction than placebo in adults without diabetes, and fewer major cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes. The findings apply to those studied populations and trial conditions.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
February 1, 2023
The reviewed studies reported substantial weight reductions in some participants with specific genetic diagnoses. The cohorts were very small, and the Bardet-Biedl and Alström trial reported inconclusive results for the Alström subgroup.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
February 1, 2026
The reviewed obesity trial reported greater weight reduction than placebo, and the reviewed liver-disease trial reported more participants with improvement in steatohepatitis without worsening fibrosis. Both are mid-stage studies with substantial remaining uncertainty.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
None registered
Both reviewed trials reported fewer new vertebral fractures with teriparatide than with the comparator. The active-comparator trial did not find a statistically significant difference for its nonvertebral fragility-fracture endpoint.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
None registered
The reviewed trials reported reductions in visceral adipose tissue, and the smaller trial also reported a modest reduction in liver fat. These studies do not establish long-term clinical outcomes or effects outside the studied HIV populations.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
July 17, 2021
The reviewed obesity trial reported greater weight reduction with tirzepatide than placebo, and the reviewed type 2 diabetes trial reported lower glycated hemoglobin and body weight than placebo. These trials do not answer every population, long-term outcome, or post-discontinuation question.↗↗